Akebia TherapeuticsvsMerck & Company

AKBA and MRK stock compared: price, dividend, valuation and results, from SEC filings.

AKBA

Akebia Therapeutics, Inc.

$0.40

Value $107M

-10.91%
AKBA's page

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

Akebia Therapeutics (AKBA) has a market value of $107M and Merck & Company (MRK) $354B. Over the last year, with dividends, AKBA moved -76.0% and MRK +58.8%. Dividend yield: AKBA none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AKBA$107M

    MRK$354B

    MRK is 3,305 times AKBA

  • Revenue, 12 months

    AKBA$197M

    MRK$67.4B

    MRK is 342 times AKBA

  • Net income, 12 months

    AKBA-$45M

    MRK$2.5B

  • Operating margin

    AKBA-15.7%

    MRK–

  • ROIC

    AKBA-31.3%

    MRK3.9%

    35.2 points apart

  • P/E

    AKBA–

    MRK144.5

  • Dividend yield

    AKBA0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    AKBA-85.9%

    MRK+98.6%

    184.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AKBA-85.9%

MRK+98.6%

010020020222023202420252026
Returns by period
PeriodAKBAWith dividendsMRKWith dividends
1 year since November 14, 2025-76.0%Price -76.0%+58.8%Price +54.3%
3 years since November 17, 2023-60.0%-26.3% a yearPrice -60.0%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021-85.9%-32.4% a yearPrice -85.9%+98.6%+14.7% a yearPrice +70.5%
10 years since November 17, 2016-95.5%-26.7% a yearPrice -95.5%+225.1%+12.5% a yearPrice +139.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AKBAAkebia TherapeuticsMRKMerck & Company

Valuation

AKBAMRK
Valuation
Price$0.40$143.37
Market value$107M$354B
Enterprise value (EV)–$399B
P/E–144.5
P/E, 5-year median–14.8
P/B5.37.9
EV/EBIT–83.7
Free cash flow yield12.9%4.2%

Results and growth

AKBAMRK
Results and growth
Revenue, 12 months$197M$67.4B
Net income, 12 months-$45M$2.5B
Free cash flow, 12 months$14M$14.7B
Earnings per share, 12 months-$0.16$0.98
Revenue growth, year on year47.5%1.3%
Revenue growth a year, past-4.3%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

AKBAMRK
Margins and returns on capital
Gross margin78.9%71.8%
Operating margin-15.7%–
Net margin-22.6%3.6%
ROIC-31.3%3.9%
ROE-151.6%5.2%

Balance sheet

AKBAMRK
Balance sheet
Cash$159M$9.7B
Total debt$60M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

AKBAMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AKBA or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Akebia Therapeutics or Merck & Company?

By market value, Merck & Company ($354B) is about 3,304.8 times Akebia Therapeutics ($107M), at today's prices.

How did AKBA and MRK stock do over the last 10 years?

Since November 17, 2016, AKBA's price moved -95.5% and MRK's +139.6%. With dividends: AKBA -95.5% (-26.7% a year), MRK +225.1% (+12.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, AKBA or MRK?

The dividend yield at today's price is none for Akebia Therapeutics and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Akebia Therapeutics or Merck & Company?

Over the last twelve months, the net margin was -22.6% for Akebia Therapeutics and 3.6% for Merck & Company, and the operating margin -15.7% and –. Revenue was $197M and $67.4B.

Which is the better investment, Akebia Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.